Literature DB >> 15388369

[Evolution of therapeutic practices and survival of ovarian cancer in Bourgandi between 1982-1996: a registry-based study].

L Benoit1, J P Désir, J Fraisse, L Arnould, J Cuisenier.   

Abstract

OBJECTIVE: The aim of this study is to describe the evolution of therapeutic practices and the evolution of survival between 1982 and 1996 in a population of ovarian carcinomas. All the patients were registered in the "Registre des Cancers Gynécologiques de Côte-d'Or-France". POPULATION AND METHODS: During this period, 546 cases of ovarian cancers were registered. Data about FIGO staging at the diagnosis, histologic type, initial surgical procedures and survival were studied.
RESULTS: During this period, 61.7% of the patients had a complete resection of their tumor. The frequency of complete removal increased significantly during the period of this study. Complete removal moved from 56%, between 1982 and 1984, up to 75%, between 1993 and 1996. Complete removal was possible in 98.1% of the FIGO stage 1 cases while it was possible in only 18.3% of the stage IV. 76.9% of the patients younger than 50 years old had a complete removal while only 29% of the women older than 80 years old had a complete removal. Fifty percent of stage I received chemotherapy as long as 85% of patients younger than 50 years old. After 1993, only 2.6% of them had radiotherapy. The global survival rate at 5 years was 35.4%.
CONCLUSIONS: Surgery is the major procedure to obtain a complete remission of ovarian cancer. The efficacy of current chemotherapies may modify the initial management of these tumors, particularly in modifying the chronology of the different therapeutic sequences.

Entities:  

Mesh:

Year:  2004        PMID: 15388369     DOI: 10.1016/j.anchir.2004.04.018

Source DB:  PubMed          Journal:  Ann Chir        ISSN: 0003-3944


  1 in total

1.  [A retrospective study of ovarian cancer with a median follow of 42 months].

Authors:  Fanomezantsoa Raherinantenaina; Solonirina Davidà Rakotomena; Nomeharisoa Rodrigue Emile Hasiniatsy; Felantsoa Auberlin Rakototiana; Florine Rafaramino; Hery Nirina Rakoto Ratsimba
Journal:  Pan Afr Med J       Date:  2015-03-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.